Skip to main content

Published locations for Dupilumab outcomes stable at end of open label atopic dermatitis study

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Dupilumab outcomes stable at end of open label atopic dermatitis study

User login

  • Reset your password
  • /content/dupilumab-outcomes-stable-end-open-label-atopic-dermatitis-study
  • /edermatologynews/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label-atopic
  • /familypracticenews/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label-atopic
  • /fedprac/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label-atopic-dermatitis
  • /internalmedicinenews/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label
  • /pediatricnews/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label-atopic
  • /pediatrics/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label-atopic
  • /internalmedicine/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label-atopic
  • /dermatology/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label-atopic
  • /familymedicine/article/263358/atopic-dermatitis/dupilumab-outcomes-stable-end-open-label-atopic